NS Pharma scores breakthrough therapy status for DMD therapy

28 Jul 2023
www.pharmaceutical-technology.com
Gene TherapyBreakthrough TherapyOligonucleotideDrug ApprovalClinical Study
NS Pharma scores breakthrough therapy status for DMD therapy
Preview
Source: Pharmaceutical Technology
Robert Barrie
NS Pharma scores breakthrough therapy status for DMD therapy
Preview
Source: Pharmaceutical Technology
Duchenne Muscular Dystrophy is one of the more prevalent genetic conditions – it affects 1 in every 3,500 male births worldwide. Image credit: Shutterstock/ChiccoDodiFC
The US Food and Drug Administration (FDA) has granted NS Pharma’s NS-089/NCNP-02 breakthrough therapy designation in a move that will help ramp up the future treatment options for Duchenne Muscular Dystrophy (DMD).
The news follows another recent FDA win for NS Pharma, which is owned by Japanese pharmaceutical company Nippon Shinyaku, after its therapy was awarded a rare paediatric disease (RPD) designation earlier in July.
Recommended Reports
NS Pharma scores breakthrough therapy status for DMD therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Mitoxantrone Hydrochloride in Neuroblastoma GlobalData
NS Pharma scores breakthrough therapy status for DMD therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Pazopanib Hydrochloride in Neuroblastoma GlobalData
View allCompanies IntelligenceNippon Shinyaku Co LtdNS Pharma, Inc.View all
A first-in-human clinical trial (NCT04129294) in six Japanese patients with DMD amenable to exon 44 skipping showed that the therapy increased dystrophin protein expression, and improved the motor function of patients as measured by The North Star Ambulatory Assessment. NS-089/NCNP-02 is an antisense nucleotide that helps cells skip over a particular exon. In the case of DMD patients, this is the mutated – and therefore dysfunctional – exon 44 in the DMD gene.
Nippon Shinyaku discovered NS-089/NCNP-02 in a joint research project with the National Center of Neurology and Psychiatry in Tokyo. NS Pharma is aiming to make NS-089/NCNP-02 the first DMD therapy for exon 44 skipping. Sarepta already has marketed antisense oligonucleotide therapies like Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) that target exon 51, exon 53, and exon 45 respectively. NS Pharma itself has an approved exon 53 skipping treatment too – Viltepso (viltolarsen).
Sarepta was recently in the news after the FDA approved the much-anticipated gene therapy Elevidys (delandistrogene moxeparvovec-rokl). The treatment, which joined an exclusive club of the 32 FDA-approved cell and gene therapies, is for children with DMD who have a confirmed mutation in the DMD gene. The Muscular Dystrophy Association hailed the therapy as “ground-breaking”.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.